• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma

Article

Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.

vemurafenib (Brand name:

Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.

Related Videos
Dr Carrie Kitko
Merrill H. Stewart, MD
Nicolas Ferreyros, managing director, Community Oncology Alliance
Dr Ibrahim Aldoss
Jody Agena, PharmD, MBA, director of pharamcy operations, Virginia Cancer Specialists
Rachel Rohaidy, MD
Mansi Shah, MD
Miriam Freimer, MD
Related Content
FDA approved | Image credit: DG-Studio – stock.adobe.com

FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma

July 2nd 2025
Article

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Read More

Managed Care Cast

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

July 1st 2025
Podcast

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.

Listen

The mean percent change in body weight from the obesity cohort from baseline to 52 weeks ranged from −12.3% to −16.2% to −16.2%. | Image Credit: ricka_kinamoto - stock.adobe.com

Weight-Loss Drug Maridebart Cafraglutide Shows Efficacy in Phase 2 Trial

July 1st 2025
Article

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Read More

Managed Care Cast

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

June 24th 2025
Podcast

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

Listen

Despite the AI-ECG model’s potential, the authors cautioned it must be evaluated in a structured clinical framework to ensure that it improves established monitoring methods rather than replaces them. | Image credit: Yan - stock.adobe.com

AI-Based Electrocardiogram Interpretation Detects LVSD in Muscular Dystrophy

June 30th 2025
Article

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

Read More

CLL cells | Image Credit: © sovova - stock.adobe.com

MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL

June 30th 2025
Article

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.